Literature DB >> 2647576

Differential effects of atropine and a cholecystokinin receptor antagonist on pancreatic secretion.

G Adler1, M Reinshagen, I Koop, B Göke, A Schafmayer, L C Rovati, R Arnold.   

Abstract

The present study evaluates the effect of atropine and of the cholecystokinin receptor antagonist loxiglumide on feedback regulation of basal pancreatic secretion in 6 healthy volunteers. The intraduodenal instillation of the protease inhibitor camostate reduced enzymatic activities of trypsin and chymotrypsin by 80%. This was accompanied by a strong increase in amylase and lipase output. The intravenous infusion of atropine (5 micrograms/kg.h) completely abolished the stimulatory effect of camostate on enzyme output. The infusion of loxiglumide (10 mg/kg.h) caused no changes in camostate-induced stimulation of enzyme output. Plasma levels of cholecystokinin were not altered after intraduodenal instillation of camostate whether atropine, loxiglumide, or saline were infused. We suggest that the protease inhibitor camostate, by inhibition of the enzymatic activity of trypsin and chymotrypsin, interferes with feedback regulation of basal pancreatic secretion in humans, and this mechanism is predominantly mediated by the cholinergic system.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2647576     DOI: 10.1016/0016-5085(89)91636-3

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  15 in total

Review 1.  Pancreatic enzyme replacement therapy.

Authors:  P Layer; J Keller; P G Lankisch
Journal:  Curr Gastroenterol Rep       Date:  2001-04

2.  Regulation of postprandial mesenteric blood flow in humans: evidence for a cholinergic nervous reflex.

Authors:  C Sieber; C Beglinger; K Jaeger; P Hildebrand; G A Stalder
Journal:  Gut       Date:  1991-04       Impact factor: 23.059

3.  Effect of a cholecystokinin receptor antagonist (loxiglumide) on gallbladder contractile function in guinea pigs.

Authors:  K Tsubo; M Arai; H Omachi; K Mitamura
Journal:  J Gastroenterol       Date:  1996-08       Impact factor: 7.527

Review 4.  Perspectives of CCK antagonists in pancreatic research and clinical use. Part I.

Authors:  L C Rovati
Journal:  Int J Pancreatol       Date:  1991-04

5.  Effect of oral protease inhibitor administration on gallbladder motility in patients with mild chronic pancreatitis.

Authors:  M Sugiyama; Y Atomi; N Wada; A Kuroda; T Muto
Journal:  J Gastroenterol       Date:  1997-06       Impact factor: 7.527

6.  Influence of high-dose pancreatic enzyme treatment on pancreatic function in healthy volunteers.

Authors:  H Friess; J Kleeff; P Malfertheiner; M W Müller; K Homuth; M W Büchler
Journal:  Int J Pancreatol       Date:  1998-04

Review 7.  Pancreatic enzymes in chronic pancreatitis.

Authors:  P Layer; G Holtmann
Journal:  Int J Pancreatol       Date:  1994-02

8.  Hepatic and pancreatic metabolism and biliary excretion of the protease inhibitor camostat mesilate.

Authors:  K Beckh; H Weidenbach; F Weidenbach; R Müller; G Adler
Journal:  Int J Pancreatol       Date:  1991 Nov-Dec

9.  Dissociation of cholecystokinin and pancreaticobiliary response to intraduodenal bile acids and cholestyramine in humans.

Authors:  I Koop; S Dorn; H Koop; S Witzleb; C Beglinger; A Schafmayer; R Arnold
Journal:  Dig Dis Sci       Date:  1991-11       Impact factor: 3.199

10.  Mechanism of galanin's inhibitory action on pancreatic enzyme secretion: modulation of cholinergic transmission--studies in vivo and in vitro.

Authors:  K H Herzig; G Brunke; I Schön; M Schäffer; U R Fölsch
Journal:  Gut       Date:  1993-11       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.